nav-left cat-right
cat-right

Immunotherapeutics & Immunomonitoring Confere...

GTC is proud to present the 7th Immunotherapeutics & Immunomonitoring Conference held on January 29-30, 2015 in San Diego, CA. Leading experts will present about novel findings and developments in the constantly changing area of immunological assays and procedures. They will also discuss recent advances in immunotherapy, as they relate to various immunotherapy modalities, specific cancers, cell subsets, animal models, and...

Cytokines & Inflammation Conference on Januar...

GTCbio invites you to the 13th Annual Cytokines & Inflammation Conference, held on January 29-30, 2015 in San Diego, CA. Some topics that will be discussed include developments in the therapeutic application of cytokines and proposal of new targets, the complex relationship between the immune system and microbes in the homeostasis of mucosal tissues, new findings in the biology and regulation of IL-23 and IL-17, novel...

3rd Immunogenicity and Immunotoxicity Conference o...

The conference will cover important progress made in the areas of therapeutic protein immunogenicity and immunotoxicity evaluation such as protein aggregation, clinical relevance and assessment of immunogenicity, mitigation of immunogenicity-related risks, biosimilar development, and immunotoxicity evaluation strategies. Guests will get an up-to-date understanding of the mechanisms and consequences of protein aggregation and...

Novel Immunotherapeutics Summit on Jan 29-30,2015 ...

GTCbio invites you to the Novel Immunotherapeutics Summit, which takes place January 29-30, 2015 in San Diego, CA. The summit will have a balance of industry and academia, so delegates have the opportunity to network with colleagues from different sectors and gain fresh perspective on the various research happening. The summit has three concurrent conferences: 13th Cytokines & Inflammation This meeting provides a forum...

Possible Cause Discovered For Failure of Targeted ...

The failure of experimental liver cancer therapies directed specifically against the EGFR protein is presumably the result of insufficiently specific patient selection. This is the conclusion that can be drawn from data that were obtained within the framework of a project carried out by an Austrian Science Fund FWF doctoral programme, and that have now been published in NATURE Cell Biology. The data prove that the...

Seegene Receives US Patent for TOCE Technology

Gaithersburg, Maryland and SEOUL, Korea, November 19, 2014 - Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies, today announced that it has been issued a United States Patent, No. 8,809,239, for its tagging oligonucleotide capture and extension (TOCE™) technology, which enables highly multiplexed target amplification and detection in a single tube. TOCE™ technology is now IP protected in the...

The Market for Therapeutic Biologicals is Evolving...

The Convergence of New Biologicals and the Growth of Biosimilars Will Require Changes at FDA according to Greystone Research Associates (Amherst, NH) – Activity in the biological drug sector is set to escalate, as a growing number of drug candidates reach the market and the number of applications requesting marketing authorization for biosimilars increases to a level that will force the FDA to institute new review...

Stem cells from human body fat used to deliver tre...

Johns Hopkins researchers say they have successfully used stem cells derived from human body fat to deliver biological treatments directly to the brains of mice with the most common and aggressive form of brain tumor, significantly extending their lives. In the mouse experiments, the Johns Hopkins investigators used mesenchymal stem cells (MSCs) – which have an unexplained ability to seek out cancer and other damaged...

NIH lays out plan to work exome data into clinical...

Having seen the cost of exome sequencing tumble in recent years, the National Institutes of Health (NIH) has decided now is the time to jump-start its genomic medicine program. The upshot is more clinical research programs will soon have access to exome sequencing capabilities and NIH support with management of the resulting data. NIH has branded the two-year plan the Clinical Center Genomics Opportunity (CCGO) and committed...

Positing Parkinson’s as an autoimmune diseas...

Parkinson’s disease, like Alzheimer’s disease, is one of the leading neurodegenerative issues being targeted by the biopharmaceutical and life sciences industries today. It is the result of the death of neurons responsible for producing dopamine, which the Parkinson’s Disease Foundation describes as “A chemical messenger that regulates movement by assisting in the effective communication (transmission) of...
Page 1 of 13012345...102030...Last »